Organism Function
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
Glucagon-Like Peptide 1, Industry, Market, Effectiveness, Oral cavity, production, injectables, Orals, orforglipron, Manufacture, GLP-1s
A closer look at pharmas top patent losses in 2025
Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023
Arch-backed HC Bioscience closes doors after seeing early data for tRNA asset
Vision, hydrocortisone, Bioscience
AAD25: Ahead of CSU filing, Novartis’ BTK inhibitor shows sleep benefits
Chronic Spontaneous Urticaria, remibrutinib, Sleep, CSU, Novartis
Hims eyes growth in its weight loss business, despite end of semaglutide shortage
semaglutide, weight loss business, United States Food and Drug Administration, Growth, Hims
AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial
Rosnilimab, PD-1 agonist, rheumatoid arthritis, Phase 2b trial, immune modulation, AnaptysBio, autoimmune disease
Eisai Anticipates Growth Acceleration for Alzheimer’s Drug Leqembi Despite Slow Initial Uptake
Leqembi, Alzheimer’s disease, Eisai, expansion phase, sales growth, diagnostics, maintenance dosing, patient adoption
EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies
DURAVYU, vorolanib, wet AMD, anti-VEGF therapy, EyePoint Pharmaceuticals, clinical trial results, stock price movement
Novo Nordisk Projects Slower Growth for 2025, Targets CagriSema Approval in 2026
Novo Nordisk, 2025 outlook, CagriSema, obesity treatment, pharmaceutical industry, Wegovy, sales growth, regulatory approval
FDA Approves Roche’s Susvimo for Diabetic Macular Edema: A Breakthrough in Continuous Delivery Eye Treatment
Susvimo, ranibizumab, diabetic macular edema, DME, Roche, FDA approval, continuous delivery, eye implant, vision improvement